Pharmaceuticals, Biotech and Life Sciences - Capital Markets

Healthcare innovations cannot happen without capital. It can take years – even decades – before a biotech company brings a new medication to market, while product-focused companies also need cash to carry out clinical trials and maintain operations. As demand for more innovative products increases, and with Canada’s pharmaceutical sector trying to assert itself as a major player in a highly competitive global industry, the need for financing has never been greater.

Companies in this sector need to tap into a variety of financing arrangements, including initial public offerings, series raises, debt offerings, royalty purchase agreements and more. They also need current information on regulatory matters related to corporate finance transactions, including advising on trading, registration, settlement and compliance issues.

These issues require an expert group that knows how to work with banks, pension funds, venture capital, private equity and other capital market players. Our Capital Markets Group has a solid track record advising on everything from private placements to public offerings to alternative listing methods such as reverse takeovers and CPC transactions. We have extensive experience with a wide variety of complex financing methods.

As this industry continues to evolve rapidly, finding the right financing to scale up your operations and ensure your discoveries come to market is key.

Recent experience


Canadian Counsel to the Underwriters in connection with AbCellera’s IPO and Listing on the NASDAQ.  Credit Suisse Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Berenberg Capital Markets LLC, SVB Leerink LLC abd BMO Capital Markets Corp. acted as underwriters in the IPO.

Learn more about our work in connection with AbCellera’s IPO and listing on the NASDAQ
A clinical laboratory microscope

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. in its $45 million public offering.  The offering was made through a syndicate of underwriters with Jefferies and Piper Sandler as joint book running managers for the offering and Oppenheimer & Co. as lead manager.

Learn more about our work with Milestone Pharmaceuticals Inc.
A pipette filling vaccine bottles

Fusion Pharmaceuticals

Fusion Pharmaceuticals in its $212.5 million IPO.  Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.

Learn more about our work with Fusion Pharmaceuticals
Scientist holding a test tube while working with a microscope

Acasti Pharma Inc.

Acasti Pharma Inc. in connection with its underwritten public offering of units for aggregate gross proceeds of $11.5 million

Learn more about our work with Acasti Pharma Inc.
Female scientist in a lab
Find more deals and cases


Related service